Summary
• Nutex Health Inc. shares rose 10.5% after reporting strong Q3 results with $723.6 million in revenue, a 225.5% year-over-year increase.
• Net income surged to $59 million, a turnaround from a $9.5 million loss last year, with diluted earnings per share at $8.87.
• The stock’s year-to-date gain reached 261.8%, supported by a recent “Buy” rating from analysts and increased investor interest.
Nutex Health Inc. (NASDAQ: NUTX) saw its shares climb 10.5%, reaching a price of $123.94 in after-hours trading from a prior close of $112.19. This notable increase reflects positive market reception following the company’s recent financial disclosures without a clear catalyst.
Earnings Spark Strong After-hours Rally
Nutex Health reported its financial results for the third quarter and year-to-date on November 19, 2025. The company delivered a remarkable total revenue of $723.6 million for the first nine months of 2025, a significant 225.5% increase year-over-year from $222.3 million in the same period of 2024. Additionally, the net income attributable to Nutex Health soared to $59 million, recovering from a net loss of $9.5 million reported last year.
Furthermore, the company reported diluted income per share of $8.87 compared to a loss of $1.91 during the first nine months of 2024. A robust adjusted EBITDA of $243 million indicated a striking 1408.6% increase, up from $16.1 million last year. These figures highlight substantial operational improvements and financial growth as Nutex Health continues to expand its healthcare delivery systems, comprising state-of-the-art micro hospitals and outpatient departments across 11 states.
Ongoing Growth and Market Performance
The stock’s recent price action demonstrates a strong upward trend driven by impressive financial metrics. Year-to-date, Nutex Health has achieved a remarkable increase of 261.8% and a staggering yearly performance climb of 397.6%. The company’s average volume over the last three months stands at approximately 137,582 shares with a 10-day average volume of 232,773, suggesting a solid interest from investors.
From a technical perspective, Nutex Health’s RSI currently sits at 60.52, indicating bullish momentum. Additionally, the stock has exhibited a 52-week low of 386.91 and a weekly performance decline of 6.8%, although it rebounded with the latest results.
Investors should be aware that the company recently received a “Buy” rating from analysts, further solidifying confidence in its growth trajectory.
Recent SEC Filings
On November 19, Nutex Health also filed an 8-K disclosing the latest financial results. This filing reflects the company’s ongoing transparency and commitment to providing stakeholders with up-to-date data on financial performance.
The company had previous 8-K filings on November 18 related to its second-quarter and restated first-quarter results, offering insights into its consistent growth pattern over the past quarters.